Skip to main content
Clinical Trials/NCT01609634
NCT01609634
Completed
N/A

A Randomised, Controlled, Double-blind Trial to Investigate the Effects of a New Infant Formula in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety.

Danone Asia Pacific Holdings Pte, Ltd.2 sites in 1 country541 target enrollmentJuly 2012
ConditionsHealthy

Overview

Phase
N/A
Intervention
Not specified
Conditions
Healthy
Sponsor
Danone Asia Pacific Holdings Pte, Ltd.
Enrollment
541
Locations
2
Primary Endpoint
Weight gain per day
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This study is initiated to investigate the effect of a new infant formula in healthy term subjects on growth, body composition, tolerance and safety.

Detailed Description

This is a "best after breast design" to measure the effect of this new infant formula in healthy term subjects on growth, body composition, tolerance and safety including immune status, gut microbiota, and early indicators (markers) of disease. These markers will be explored if they could predict the risk of eczema and other allergic disease, and to evaluate if these markers are influenced by early nutrition.

Registry
clinicaltrials.gov
Start Date
July 2012
End Date
December 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy term infants (gestational age ≥ 37 and ≤ 42 weeks)
  • Age ≤ 28 days
  • Birth weight within normal range for gestational age and sex (3rd to 90th percentile according to applicable growth charts)
  • Head circumference at birth within normal range (3rd to 90th percentile of the chart)
  • Chinese, Malay, or Indian ethnicity
  • Written informed consent from parent(s)
  • Currently reside in Singapore and with the intention to reside in Singapore for at least the next 2 years
  • Exclusion criteria for the pregnant women/parents:
  • Pregnant women / mothers who are currently participating or will participate in any other (clinical) study involving investigational or marketed products during pregnancy and/or lactation.
  • Pregnant women / mothers known to suffer from hepatitis B or human immunodeficiency virus (HIV)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Weight gain per day

Time Frame: 17 weeks

Weight gain per day from randomisation until 17 weeks of age.

Sum of skin fold thicknesses

Time Frame: 24 months

Sum of skin fold thicknesses: triceps, biceps, suprailiac, subscapular until 24 months of age in subjects receiving the test product 1, test product 2, or control product.

Total weight gain

Time Frame: 12 months

Total weight gain from birth until 12 months of age

Secondary Outcomes

  • Weight, length, BMI, head circumference, mid-upper arm circumference, subscapular skinfold, triceps skinfold(24 months)
  • Recumbent length, head circumference, mid-upper arm circumference, skin folds(17 weeks)
  • Skin-fold thickness(12 months)

Study Sites (2)

Loading locations...

Similar Trials